Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas

Edward Dropcho, Steven S. Rosenfeld, Richard B. Morawetz, Jiri Vitek, Michael Brothers, Tammy Gorum, Susan Bell, G. Yancey Gillespie, Michael Glantz, M. Stephen Mahaley, S. Clifford Schold

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Purpose: This phase II study was performed to assess the response of patients with newly diagnosed, untreated malignant gliomas (anaplastic astrocytoma [AA] and glioblastoma multiforme [GBM]) to intracarotid (IC) eisplatin. Patients and Methods: Eligibility criteria included surgical intervention limited to biopsy only, measurable contrast-enhancing tumor, and unilateral tumor location within the vascular territory of one internal carotid artery. Patients were scheduled to receive four infusions of IC cisplatin (75 mg/m2 every 4 weeks) before beginning standard radiotherapy. Twenty-six patients were treated, and 22 were assessable for response. Results: Ten patients (45%) showed a greater than 25% decrease in the enhancing tumor area before radio therapy with stabilization or improvement of neurologic deficits, and three patients (14%) had a greater than 70% decrease in tumor area. The likelihood of response to IC cisplatin was not clearly linked to patient age, tumor histology, or pretreatment tumor size. Myelosuppression, nephrotoxicity, and ototoxicity were mild. Optic neuropathy occurred in one patient, seizures in two, and fatal postinfusion cerebral edema in one. Conclusion: This study design, which permits assessment of the drug sensitivity of the untreated glioma, has shown definite antitumor activity of IC cisplatin in newly diagnosed malignant glioma patients.

Original languageEnglish (US)
Pages (from-to)452-458
Number of pages7
JournalJournal of Clinical Oncology
Volume10
Issue number3
StatePublished - 1992
Externally publishedYes

Fingerprint

Glioma
Cisplatin
Neoplasms
Therapeutics
Optic Nerve Diseases
Brain Edema
Astrocytoma
Internal Carotid Artery
Glioblastoma
Neurologic Manifestations
Radio
Blood Vessels
Histology
Seizures
Radiotherapy
Biopsy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dropcho, E., Rosenfeld, S. S., Morawetz, R. B., Vitek, J., Brothers, M., Gorum, T., ... Clifford Schold, S. (1992). Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. Journal of Clinical Oncology, 10(3), 452-458.

Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. / Dropcho, Edward; Rosenfeld, Steven S.; Morawetz, Richard B.; Vitek, Jiri; Brothers, Michael; Gorum, Tammy; Bell, Susan; Yancey Gillespie, G.; Glantz, Michael; Stephen Mahaley, M.; Clifford Schold, S.

In: Journal of Clinical Oncology, Vol. 10, No. 3, 1992, p. 452-458.

Research output: Contribution to journalArticle

Dropcho, E, Rosenfeld, SS, Morawetz, RB, Vitek, J, Brothers, M, Gorum, T, Bell, S, Yancey Gillespie, G, Glantz, M, Stephen Mahaley, M & Clifford Schold, S 1992, 'Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas', Journal of Clinical Oncology, vol. 10, no. 3, pp. 452-458.
Dropcho E, Rosenfeld SS, Morawetz RB, Vitek J, Brothers M, Gorum T et al. Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. Journal of Clinical Oncology. 1992;10(3):452-458.
Dropcho, Edward ; Rosenfeld, Steven S. ; Morawetz, Richard B. ; Vitek, Jiri ; Brothers, Michael ; Gorum, Tammy ; Bell, Susan ; Yancey Gillespie, G. ; Glantz, Michael ; Stephen Mahaley, M. ; Clifford Schold, S. / Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. In: Journal of Clinical Oncology. 1992 ; Vol. 10, No. 3. pp. 452-458.
@article{f4f806e0278b4491810a371e752a8480,
title = "Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas",
abstract = "Purpose: This phase II study was performed to assess the response of patients with newly diagnosed, untreated malignant gliomas (anaplastic astrocytoma [AA] and glioblastoma multiforme [GBM]) to intracarotid (IC) eisplatin. Patients and Methods: Eligibility criteria included surgical intervention limited to biopsy only, measurable contrast-enhancing tumor, and unilateral tumor location within the vascular territory of one internal carotid artery. Patients were scheduled to receive four infusions of IC cisplatin (75 mg/m2 every 4 weeks) before beginning standard radiotherapy. Twenty-six patients were treated, and 22 were assessable for response. Results: Ten patients (45{\%}) showed a greater than 25{\%} decrease in the enhancing tumor area before radio therapy with stabilization or improvement of neurologic deficits, and three patients (14{\%}) had a greater than 70{\%} decrease in tumor area. The likelihood of response to IC cisplatin was not clearly linked to patient age, tumor histology, or pretreatment tumor size. Myelosuppression, nephrotoxicity, and ototoxicity were mild. Optic neuropathy occurred in one patient, seizures in two, and fatal postinfusion cerebral edema in one. Conclusion: This study design, which permits assessment of the drug sensitivity of the untreated glioma, has shown definite antitumor activity of IC cisplatin in newly diagnosed malignant glioma patients.",
author = "Edward Dropcho and Rosenfeld, {Steven S.} and Morawetz, {Richard B.} and Jiri Vitek and Michael Brothers and Tammy Gorum and Susan Bell and {Yancey Gillespie}, G. and Michael Glantz and {Stephen Mahaley}, M. and {Clifford Schold}, S.",
year = "1992",
language = "English (US)",
volume = "10",
pages = "452--458",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas

AU - Dropcho, Edward

AU - Rosenfeld, Steven S.

AU - Morawetz, Richard B.

AU - Vitek, Jiri

AU - Brothers, Michael

AU - Gorum, Tammy

AU - Bell, Susan

AU - Yancey Gillespie, G.

AU - Glantz, Michael

AU - Stephen Mahaley, M.

AU - Clifford Schold, S.

PY - 1992

Y1 - 1992

N2 - Purpose: This phase II study was performed to assess the response of patients with newly diagnosed, untreated malignant gliomas (anaplastic astrocytoma [AA] and glioblastoma multiforme [GBM]) to intracarotid (IC) eisplatin. Patients and Methods: Eligibility criteria included surgical intervention limited to biopsy only, measurable contrast-enhancing tumor, and unilateral tumor location within the vascular territory of one internal carotid artery. Patients were scheduled to receive four infusions of IC cisplatin (75 mg/m2 every 4 weeks) before beginning standard radiotherapy. Twenty-six patients were treated, and 22 were assessable for response. Results: Ten patients (45%) showed a greater than 25% decrease in the enhancing tumor area before radio therapy with stabilization or improvement of neurologic deficits, and three patients (14%) had a greater than 70% decrease in tumor area. The likelihood of response to IC cisplatin was not clearly linked to patient age, tumor histology, or pretreatment tumor size. Myelosuppression, nephrotoxicity, and ototoxicity were mild. Optic neuropathy occurred in one patient, seizures in two, and fatal postinfusion cerebral edema in one. Conclusion: This study design, which permits assessment of the drug sensitivity of the untreated glioma, has shown definite antitumor activity of IC cisplatin in newly diagnosed malignant glioma patients.

AB - Purpose: This phase II study was performed to assess the response of patients with newly diagnosed, untreated malignant gliomas (anaplastic astrocytoma [AA] and glioblastoma multiforme [GBM]) to intracarotid (IC) eisplatin. Patients and Methods: Eligibility criteria included surgical intervention limited to biopsy only, measurable contrast-enhancing tumor, and unilateral tumor location within the vascular territory of one internal carotid artery. Patients were scheduled to receive four infusions of IC cisplatin (75 mg/m2 every 4 weeks) before beginning standard radiotherapy. Twenty-six patients were treated, and 22 were assessable for response. Results: Ten patients (45%) showed a greater than 25% decrease in the enhancing tumor area before radio therapy with stabilization or improvement of neurologic deficits, and three patients (14%) had a greater than 70% decrease in tumor area. The likelihood of response to IC cisplatin was not clearly linked to patient age, tumor histology, or pretreatment tumor size. Myelosuppression, nephrotoxicity, and ototoxicity were mild. Optic neuropathy occurred in one patient, seizures in two, and fatal postinfusion cerebral edema in one. Conclusion: This study design, which permits assessment of the drug sensitivity of the untreated glioma, has shown definite antitumor activity of IC cisplatin in newly diagnosed malignant glioma patients.

UR - http://www.scopus.com/inward/record.url?scp=0026510256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026510256&partnerID=8YFLogxK

M3 - Article

C2 - 1311026

AN - SCOPUS:0026510256

VL - 10

SP - 452

EP - 458

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -